Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Receives “Hold” Rating from HC Wainwright

HC Wainwright reaffirmed their hold rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a report published on Wednesday, October 4th. HC Wainwright currently has a $17.00 price target on the specialty pharmaceutical company’s stock.

Several other equities research analysts have also commented on the stock. J P Morgan Chase & Co set a $10.00 price target on shares of Valeant Pharmaceuticals International and gave the company a hold rating in a research report on Monday, July 17th. Cantor Fitzgerald reaffirmed a buy rating and set a $23.00 price target on shares of Valeant Pharmaceuticals International in a research report on Tuesday, August 29th. Guggenheim assumed coverage on shares of Valeant Pharmaceuticals International in a report on Saturday, June 17th. They issued a buy rating and a $18.00 target price for the company. Wells Fargo & Company reissued an underperform rating and issued a $9.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Finally, Deutsche Bank AG set a $19.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a hold rating in a report on Monday, August 21st. Five analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have given a buy rating to the company. The stock has an average rating of Hold and an average target price of $17.71.

Valeant Pharmaceuticals International (NYSE:VRX) opened at 12.92 on Wednesday. The stock’s 50 day moving average is $13.96 and its 200-day moving average is $13.57. The company’s market capitalization is $4.50 billion. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $24.30.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The business had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. During the same quarter in the previous year, the firm earned ($0.88) EPS. Valeant Pharmaceuticals International’s revenue was down 7.7% on a year-over-year basis. On average, analysts expect that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Receives “Hold” Rating from HC Wainwright” was originally reported by BBNS and is owned by of BBNS. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/valeant-pharmaceuticals-international-inc-vrx-receives-hold-rating-from-hc-wainwright/1697654.html.

In related news, Director Schutter Richard U. De purchased 10,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Monday, August 21st. The stock was bought at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the transaction, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 5.87% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. Gruss & Co. Inc. purchased a new position in Valeant Pharmaceuticals International during the first quarter valued at approximately $104,000. Harbor Advisors LLC purchased a new stake in shares of Valeant Pharmaceuticals International in the first quarter valued at approximately $110,000. PNC Financial Services Group Inc. increased its position in shares of Valeant Pharmaceuticals International by 33.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 2,763 shares in the last quarter. Baird Financial Group Inc. purchased a new stake in shares of Valeant Pharmaceuticals International in the first quarter valued at approximately $127,000. Finally, OLD Mutual Customised Solutions Proprietary Ltd. increased its position in shares of Valeant Pharmaceuticals International by 357.7% in the first quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 11,900 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 9,300 shares in the last quarter. Institutional investors own 50.44% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Alex Cora Becomes New Manager for Boston Red Sox
Alex Cora Becomes New Manager for Boston Red Sox
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends


Leave a Reply

 
© 2006-2017 BBNS.